Skip to main content
SpringerLink
Log in

Interim results of a multicenter international comparison of misoprostol and cimetidine in the treatment of out-patients with benign gastric ulcers

  • Part 4: Clinical and Pharmacological Actions of Misoprostol, a PGE1 Analog
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

An interim analysis has been performed of a multicenter randomized double-blind parallel-group comparison of misoprostol 50 μg (low dose), misoprostol 200 μg (high dose), and cimetidine 300 mg in out-patients with endoscopically diagnosed benign gastric ulcers. The drugs were administered q.i.d. for four weeks. Endoscopic assessments were made before treatment and at four weeks. Clinical assessments and laboratory tests were made before treatment and at two and four weeks. At the interim stage 421 subjects of the target 600 patients had been recruited by 22 principal investigators in 13 countries. Demographic data were similar for all groups with the exceptions of a lower proportion of males and smokers in the cimetidine group. Therapeutic success was defined as complete healing of all gastric ulcers. Cure rates at four weeks, for all eligible patients who received at least one dose of study medication (cohort 1), were significantly lower (P=0.002) for misoprostol 50 μg (41.2%) than for misoprostol 200 μg (58.2%). There was no significant difference (P=0.86) in cure rates between the high dose misoprostol and cimetidine (59.6%) groups. Cure rates were approximately 20% higher for non-smokers than smokers in both misoprostol groups, an effect not observed with cimetidine. In all three treatment groups the incidence of complaints, including diarrhea, was similar and therapy was well tolerated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dajani EZ, Driskill D, Bianchi R, Collins P, Pappo R: SC 29333: a potent inhibitor of canine gastric secretion. Am J Dig Dis 21:1049–1057, 1976

    Google Scholar 

  2. Colton DG, Driskill DR, Phillips EL, Poy P, Dajani EZ: Effect of SC 29333 an inhibitor of gastric secretion, on canine gastric mucosal blood flow and serum gastrin levels. Arch Int Phamacodyn Ther 236:86–95, 1978

    Google Scholar 

  3. Ramage JK, Denton A, Williams JG: Duration of action of misoprostol, an orally active synthetic E1 analogue of prostaglandin. Gut 24:A973, 1983

    Google Scholar 

  4. Dajani EZ, Callison DA, Bertermann RE: Effects of Eprostaglandins on canine gastric potential difference. Am J Dig Dis 23:436–442, 1978

    Google Scholar 

  5. Colton DG, Callison DA, Dajani EZ: Effects of a prostaglandin E1 derivative, SC 29333 and aspirin on gastric ionic fluxes and potential differences in dogs. J Pharmacol Exp Ther 210:283–288, 1979

    Google Scholar 

  6. Larsen KR, Jensen NF, Davis EK, Jensen JC, Moody FG: The cytoprotective effects of (±)-15-deoxy-16-α-,β-hydroxy-16-methyl PGE1, methyl ester (SC 29333) versus aspirin in shock gastric ulcerogenesis in the dog. Prostaglandins 21(Suppl):119–124, 1981

    Google Scholar 

  7. Arvidsson S, Falt K, Haglund U: Gastric mucosal damage in sepsis—effects of pretreatment with a synthetic prostaglandin E1 analogue. Gut 1984 (in preparation)

  8. Gullikson G, Anglin C, Kessler L, Smeach S, Crowder S, Bauer R, Dajani EZ: Misoprostol prevents aspirin-induced damage in canine Heidenhain pouches. Gastroenterology 84:1176, 1983

    Google Scholar 

  9. Hunt JN, Smith JL, Jiang CL, Kessler L: Effect of synthetic prostaglandin E1-analogue on aspirin-induced gastric bleeding and secretion. Dig Dis Sci 28:897–902, 1983

    Google Scholar 

  10. Cohen MM, Clark L, Armstrong L, D'Sousa J: Reduced aspirin fecal blood loss with simultaneous administration of misoprostol (PGE1 methyl analogue). Gastroenterology 84:1126, 1983

    Google Scholar 

  11. Kessler L, Bianchi R, Callison DA, Dajani EZ: Prevention of duodenal ulcer formation in cat by E-prostaglandins. Pharmacologist 23:A42, 1981

    Google Scholar 

  12. Bianchi RG, Casler JJ, Dajani EZ: Gastric antisecretory and anti-ulcer activity of SC 29333: a synthetic E-prostaglandin analogue. Pharmacologist 23:121, 1981

    Google Scholar 

  13. Wright JP, Marks IN, Mee AS, Girdwood AH, Bornman PC, Gilinsky NH, Tobins P, Lucke W: Ranitidine in the treatment of gastric ulceration. S Afr Med J 61:155–158, 1982

    Google Scholar 

  14. Ryan FP: A comparison of ranitidine and placebo in acute treatment of gastric ulcer.In The Clinical Use of Ranitidine, JJ Misiewicz, KG Wormsley (eds). Medicine Publishing Foundation, Oxford Medicine Publishing Foundation Series 5, 1982, pp 199–203

  15. Jones DB, Rose JDR, Smith PM, Calcraft BJ: Treatment of peptic ulcer with ranitidine—a clinical trial.In The Clinical Use of Ranitidine, JJ Misiewicz, KG Wormsley (eds). Medicine Publishing Foundation, Oxford Medical Publishing Foundation Series 5, 1982 pp 183–186

  16. Pare P, Levesque D, Archambault A, Farley A, Gosselin D, Leroux P, Pilon G, Sherbaniur R, Trautman A, Tomson ABR, Quina M: Effect of ranitidine on healing of peptic ulcer.In The Clinical Use of Ranitidine, JJ Misiewicz, KG Wormsley (eds). Oxford, Oxford Medicine Publishing Foundation Series 5, 1982, pp 178–182

  17. Batterman RC, Ehrenfeld I: The influence of smoking upon the management of the peptic ulcer patient. Gastroenterology 12:575–585, 1949

    Google Scholar 

  18. Peterson WL, Sturdevant RAL, Frankl HD, Richardson CT, Isenberg JI, Elashoff JD, Sones JQ, Gross RA, McCallum RW, Fordtran JS: Healing of duodenal ulcer with an antacid regimen. N Engl J Med 297:341–345, 1977

    Google Scholar 

  19. Sonnenberg A, Muller-Lissner SA, Vogel E, Schmid P, Gonvers JJ, Peter P, Strohmeyer G, Blum AL: Predictors of duodenal ulcer healing and relapse. Gastroenterology 81:1061–1067, 1981

    Google Scholar 

  20. Van Trappen G, Jonssens SJ, Popiela T, Kulig J, Tytgat GN, Huibregtse K, Lambert R, Pauchard JP, Robert A: Effect of 15(R)-15-methyl prostaglandin E2 (Arbaprostil) on the healing of duodenal ulcer. Gastroenterology 83:357–363, 1982

    Google Scholar 

  21. Ippoliti, AF, Isenberg JI, Maxwell V: The effect of 16,16-dimethyl prostaglandin E2 on meal stimulated gastric acid secretion and serum gastrin in duodenal ulcer patients. Gastroenterology 70:488–491, 1976

    Google Scholar 

  22. Gibinski K, Rybicka J, Mikos E, Nowat A: Double blind clinical trial on gastroduodenal ulcer healing with PGE2 analogues. Gut 18:636–639, 1977

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Research, Europe, G.D. Searle and Co. Ltd., HP12 4HL, High Wycombe, Buckinghamshire, UK

    M. J. Shield MB, BS, MRCPath (Director)

Authors
  1. M. J. Shield MB, BS, MRCPath
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This paper was prepared on behalf of an international study group.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shield, M.J. Interim results of a multicenter international comparison of misoprostol and cimetidine in the treatment of out-patients with benign gastric ulcers. Digest Dis Sci 30 (Suppl 11), 178S–184S (1985). https://doi.org/10.1007/BF01309406

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01309406

Keywords

Search

Navigation